Optimal Incidence Threshold for Cost-Effective Hepatocellular Carcinoma Surveillance in Alcohol-Associated Cirrhosis
Clinical Gastroenterology and Hepatology · 2026-10
DOI: 10.1016/j.cgh.2026.09.035 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Gastroenterology and Hepatology, 2026-10. Verfasst von Ali Hajjar und 6 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Technology Assessment, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts; Mohammed Bin Salman College of Bu…. Die Arbeit nennt 55 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND & AIMS: Current guidelines recommend routine hepatocellular carcinoma (HCC) surveillance in patients with cirrhosis when annual HCC incidence exceeds 1 per 100 person-years, a threshold derived from older studies and not specific to alcohol-associated cirrhosis. However, contemporary data suggest that HCC incidence in this population is often below 1%, leaving the value of routine surveillance uncertain. METHODS: We developed a Markov-based state-transition microsimulation model to simulate the natural history of HCC and subsequent treatment pathways in patients with alcohol-associated cirrhosis in the setting of the United States. The model compared biannual surveillance with ultrasound and alpha fetoprotein vs no surveillance separately for 2 distinct cohorts: patients who continued to actively consume alcohol and patients who had achieved sustained abstinence. Inputs included the natural history of alcohol-associated cirrhosis, HCC incidence, test performance, surveillance adherence, and contemporary treatment. Sensitivity analyses examined the robustness of model assumptions and findings. RESULTS: Biannual surveillance becomes cost-effective when annual HCC incidence reached approximately 0.45 per 100 person-years using a willingness-to-pay threshold of $100,000 per quality-adjusted life year (QALY). Among active drinkers, surveillance yielded an incremental cost-effectiveness ratio of $18,952 per QALY; among abstinent patients, the incremental cost-effectiveness ratio was $56,000 per QALY. Per 100,000 patients, routine surveillance generated an estimated 2083 additional life-years and 992 QALYs in active drinkers and 3357 life-years and 1700 QALYs in abstinent patients. CONCLUSIONS: Routine biannual HCC surveillance with ultrasound and alpha fetoprotein is cost-effective for patients with alcohol-associated cirrhosis in the United States when HCC incidence exceeds 0.45 per 100 person-years, substantially below the historically cited 1 per 100 person-years threshold. Updating clinical guidelines to reflect these contemporary thresholds could improve early HCC detection in this high-risk population.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institute for Technology Assessment, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts; Mohammed Bin Salman College of Business and Entrepreneurship, King Abdullah Economic City, Saudi Arabia.
- Institute for Technology Assessment, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts; Georgia Institute of Technology, Atlanta, Georgia.
- Institute for Technology Assessment, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts; School of Business and Economics, Brandeis University, Waltham, Massachusetts.
- Institute for Technology Assessment, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
- Institute for Technology Assessment, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts; Division of Medical Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
- Department of Medicine, Baylor College of Medicine, Houston, Texas; Houston Veterans Affairs Health Services Research and Development Center of Excellence, Michael E. DeBakey Veterans Affairs Medical Center, Houston, Te…
Zitieren
APA
Hajjar, A., Julien, J., Nemutlu, G., Sahinkoc, H. M., Peters, M. L. B., Kanwal, F., & Chhatwal, J. (2026). Optimal Incidence Threshold for Cost-Effective Hepatocellular Carcinoma Surveillance in Alcohol-Associated Cirrhosis. Clinical Gastroenterology and Hepatology. https://doi.org/10.1016/j.cgh.2026.09.035
Vancouver
Hajjar A, Julien J, Nemutlu G, Sahinkoc HM, Peters MLB, Kanwal F, et al. Optimal Incidence Threshold for Cost-Effective Hepatocellular Carcinoma Surveillance in Alcohol-Associated Cirrhosis. Clinical Gastroenterology and Hepatology. 2026. doi:10.1016/j.cgh.2026.09.035
BibTeX
@article{Hajjar2026,
author = {Hajjar, Ali and Julien, Jovan and Nemutlu, Gizem and Sahinkoc, H Mert and Peters, Mary Linton B and Kanwal, Fasiha and Chhatwal, Jagpreet},
title = {Optimal Incidence Threshold for Cost-Effective Hepatocellular Carcinoma Surveillance in Alcohol-Associated Cirrhosis},
journal = {Clinical Gastroenterology and Hepatology},
year = {2026},
doi = {10.1016/j.cgh.2026.09.035}
}
EUVIMED